Published online Jun 16, 2023. doi: 10.4253/wjge.v15.i6.480
Peer-review started: April 17, 2023
First decision: May 19, 2023
Revised: May 20, 2023
Accepted: May 31, 2023
Article in press: May 31, 2023
Published online: June 16, 2023
Processing time: 57 Days and 10.8 Hours
Although esophageal candidiasis (EC) may manifest in immunocompetent individuals, there is a lack of consensus in the current literature about predisposing conditions that increase the risk of infection.
To determine the prevalence of EC in patients without human immunodeficiency virus (HIV) and identify risk factors for infection.
We retrospectively reviewed inpatient and outpatient encounters from 5 regional hospitals within the United States (US) from 2015 to 2020. International Classification of Diseases, Ninth and Tenth Revisions were used to identify patients with endoscopic biopsies of the esophagus and EC. Patients with HIV were excluded. Adults with EC were compared to age, gender, and encounter-matched controls without EC. Patient demographics, symptoms, diagnoses, medications, and laboratory data were obtained from chart extraction. Differences in medians for continuous variables were compared using the Kruskal-Wallis test and categorical variables using chi-square analyses. Multivariable logistic regression was used to identify independent risk factors for EC, after adjusting for potential confounding factors.
Of the 1969 patients who had endoscopic biopsies of the esophagus performed from 2015 to 2020, 295 patients had the diagnosis of EC. 177 of 1969 patients (8.99%) had pathology confirming the diagnosis of EC and were included in the study for data collection and further analysis. In comparison to controls, patients with EC had significantly higher rates of gastroesophageal reflux disease (40.10% vs 27.50%; P = 0.006), prior organ transplant (10.70% vs 2%; P < 0.001), immunosuppressive medication (18.10% vs 8.10%; P = 0.002), proton pump inhibitor (48% vs 30%; P < 0.001), corticosteroid (35% vs 17%; P < 0.001), Tylenol (25.40% vs 16.20%; P = 0.019), and aspirin use (39% vs 27.50%; P = 0.013). On multivariable logistic regression analysis, patients with a prior organ transplant had increased odds of EC (OR = 5.81; P = 0.009), as did patients taking a proton pump inhibitor (OR = 1.66; P = 0.03) or corticosteroids (OR = 2.05; P = 0.007). Patients with gastroesophageal reflux disease or medication use, including immunosuppressive medications, Tylenol, and aspirin, did not have a significantly increased odds of EC.
Prevalence of EC in non-HIV patients was approximately 9% in the US from 2015-2020. Prior organ transplant, proton pump inhibitors, and corticosteroids were identified as independent risk factors for EC.
Core Tip: While esophageal candidiasis (EC) is often associated with human immunodeficiency virus (HIV), the prevalence and clinical risk factors for infection in the non-HIV population are less well established. Our study found the prevalence of EC among patients without HIV in the United States to be higher than anticipated, approximately 9%, over a 5-year period. Independent risk factors for infection were prior organ transplant, proton pump inhibitor, or corticosteroid use. The findings of this study may aide clinicians in establishing an early diagnosis and treatment of EC, thereby preventing the later complications of more severe disease.